The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer

- Buffart, Laurien M., Newton, Robert U., Chinapaw, Mai J., Taaffe, Dennis R., Spry, Nigel A., Denham, James W., Joseph, David J., Lamb, David S., Brug, Johannes, Galvão, Daniel A.

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials

- D'Amico, Anthony V., Chen, Ming-Hui, de Castro, Mario, Loffredo, Marian, Lamb, David S., Steigler, Allison, Kantoff, Philip W., Denham, James W.

Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial

- Denham, James W., Wilcox, Chantelle, Gogna, Nirdosh Kumar, Kenny, Lizbeth, Duchesne, Gillian, Delahunt, Brett, McElduff, Patrick, Joseph, David, Spry, Nigel A., Lamb, David S., Tai, Keen-Hun, Matthews, John, Atkinson, Chris, Turner, Sandra, Christie, David

Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?

- Denham, James W., Steigler, Allison, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Tai, Keen-Hun, Spry, Nigel A., Gleeson, Paul S., D'Este, Catherine

Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer

- Denham, James W., Kumar, Mahesh, Turner, Sandra, Greer, Peter B., D'Este, Catherine, Steigler, Allison, Gleeson, Paul S., Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David

Measuring time to biochemical failure in the Trog 96.01 trial: when should the clock start ticking?

- Denham, James W., Steigler, Allison, Gleeson, Paul S., D'Este, Catherine, Kumar, Mahesh, Lamb, David S., Joseph, David, Spry, Nigel A., Tai, Keen-Hun, Atkinson, Chris, Turner, Sandra, Greer, Peter B.

Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer

- Denham, James W., Wilcox, Chantelle, Gogna, Nirdosh Kumar, Ebert, Martin, Delahunt, Brett, McElduff, Patrick, Joseph, David, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Atkinson, Chris, Matthews, John, Turner, Sandra, Kenny, Lizabeth, Tai, Keen-Hun

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial

- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Gogna, Nirdosh Kumar, Gill, Suki, Tan, Hendrick, Kearvell, Rachel, Murray, Judy, Ebert, Martin, Haworth, Annette, Kennedy, Angel, Delahunt, Brett, Joseph, David, Oldmeadow, Christopher, Holliday, Elizabeth G., Attia, John, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Atkinson, Chris, Matthews, John, Turner, Sandra, Kenny, Lizbeth

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Wynne, Chris, D'Este, Catherine, Lamb, David S., Joseph, David, Turner, Sandra, Matthews, John, Atkinson, Chris, North, John, Christie, David, Spry, Nigel A.

PSA response signatures: a powerful new prognostic indicator after radiation for prostate cancer?

- Denham, James W., Lamb, David S., Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Duchesne, Gillian, Ebert, Martin, Steigler, Allison, D'Este, Catherine

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

- Denham, James W., Steigler, Allison, Gleeson, Paul S., Greer, Peter B., D'Este, Catherine, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

- Denham, James W., Joseph, David, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Matthews, John, Atkinson, Chris, Tai, Keen-Hun, Christie, David, Kenny, Lizbeth, Turner, Sandra, Gogna, Nirdosh Kumar, Diamond, Terry, Delahunt, Brett, Oldmeadow, Chris, Attia, John, Steigler, Allison

Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer

- Denham, James W., Steigler, Allison, Wynne, Chris, Lamb, David S., Tai, Keen-Hun, Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Turner, Sandra, North, John, Christie, David

A methodology for the analysis of PSA response signatures

- Ebert, Martin A., Lamb, David S., Joseph, David J., Steigler, Allison, Denham, James W.

A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial

- Galvão, Daniel A., Spry, Nigel, Taaffe, Dennis R., Denham, James, Joseph, David, Lamb, David S., Levin, Greg, Duchesne, Gillian, Newton, Robert U.

A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR

- Galvão, Daniel A., Spry, Nigel, Denham, James, Taaffe, Dennis R., Cormie, Prue, Joseph, David, Lamb, David S., Chambers, Suzanne K., Newton, Robert U.

Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial

- Joseph, David, Denham, James W., Turner, Sandra, Kenny, Lizbeth, Christie, David, Tai, Keen-Hun, Gogna, NirdoshK, Kearvell, Rachel, Murray, Judy, Ebert, Martin A., Haworth, Annette, Delahunt, Brett, Steigler, Allison, Oldmeadow, Christopher, Attia, John, Lamb, David S., Spry, Nigel A., Stanley, John, Shannon, Tom, Duchesne, Gillian, Atkinson, Chris, Matthews, John H. L.

Proteins Annexin A2 and PSA in prostate cancer biopsies do not predict biochemical failure

- Lamb, David S., Sondhauss, Sven, Dunne, Jonathan C., Woods, Lisa, Delahunt, Brett, Ferguson, Peter, Murray, Judith, Nacey, John N., Denham, James W., Jordan, T. William

A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial

- Lamb, David S., Denham, James W., D'Este, Catherine, Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Duchesne, Gillian, Ebert, Martin, Steigler, Allison, Delahunt, Brett

Survival benefit confirmed for prostate cancers diagnosed by PSA testing (letter)

- Lamb, David S., Delahunt, Brett, Denham, James, Slaney, David